188 related articles for article (PubMed ID: 22053850)
21. Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy.
Babiak A; Steinhauser M; Götz M; Herbst C; Döhner H; Greiner J
Oncol Rep; 2014 Jan; 31(1):384-90. PubMed ID: 24154794
[TBL] [Abstract][Full Text] [Related]
22. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes.
Slager EH; van der Minne CE; Krüse M; Krueger DD; Griffioen M; Osanto S
J Immunol; 2004 Apr; 172(8):5095-102. PubMed ID: 15067093
[TBL] [Abstract][Full Text] [Related]
23. Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase.
Klyushnenkova EN; Kouiavskaia DV; Kodak JA; Vandenbark AA; Alexander RB
Prostate; 2007 Jul; 67(10):1019-28. PubMed ID: 17455230
[TBL] [Abstract][Full Text] [Related]
24. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
25. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3.
Consogno G; Manici S; Facchinetti V; Bachi A; Hammer J; Conti-Fine BM; Rugarli C; Traversari C; Protti MP
Blood; 2003 Feb; 101(3):1038-44. PubMed ID: 12393675
[TBL] [Abstract][Full Text] [Related]
26. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.
Jäger E; Jäger D; Karbach J; Chen YT; Ritter G; Nagata Y; Gnjatic S; Stockert E; Arand M; Old LJ; Knuth A
J Exp Med; 2000 Feb; 191(4):625-30. PubMed ID: 10684854
[TBL] [Abstract][Full Text] [Related]
27. Identification of DR9-restricted XAGE antigen on lung adenocarcinoma recognized by autologous CD4 T-cells.
Shimono M; Uenaka A; Noguchi Y; Sato S; Okumura H; Nakagawa K; Kiura K; Tanimoto M; Nakayama E
Int J Oncol; 2007 Apr; 30(4):835-40. PubMed ID: 17332921
[TBL] [Abstract][Full Text] [Related]
28. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
29. Identification of promiscuous epitopes from the Mycobacterial 65-kilodalton heat shock protein recognized by human CD4(+) T cells of the Mycobacterium leprae memory repertoire.
Mustafa AS; Lundin KE; Meloen RH; Shinnick TM; Oftung F
Infect Immun; 1999 Nov; 67(11):5683-9. PubMed ID: 10531216
[TBL] [Abstract][Full Text] [Related]
30. Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients.
Saito K; Nakayama E; Valmori D
PLoS One; 2016; 11(3):e0150623. PubMed ID: 26937656
[TBL] [Abstract][Full Text] [Related]
31. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
[TBL] [Abstract][Full Text] [Related]
32. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.
Robbins PF; El-Gamil M; Li YF; Zeng G; Dudley M; Rosenberg SA
J Immunol; 2002 Nov; 169(10):6036-47. PubMed ID: 12421991
[TBL] [Abstract][Full Text] [Related]
33. Detection of spontaneous CD4+ T-cell responses in melanoma patients against a tyrosinase-related protein-2-derived epitope identified in HLA-DRB1*0301 transgenic mice.
Paschen A; Song M; Osen W; Nguyen XD; Mueller-Berghaus J; Fink D; Daniel N; Donzeau M; Nagel W; Kropshofer H; Schadendorf D
Clin Cancer Res; 2005 Jul; 11(14):5241-7. PubMed ID: 16033842
[TBL] [Abstract][Full Text] [Related]
34. SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4
Lacher MD; Bauer G; Fury B; Graeve S; Fledderman EL; Petrie TD; Coleal-Bergum DP; Hackett T; Perotti NH; Kong YY; Kwok WW; Wagner JP; Wiseman CL; Williams WV
Front Immunol; 2018; 9():776. PubMed ID: 29867922
[TBL] [Abstract][Full Text] [Related]
35. Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery.
Kono M; Kumai T; Hayashi R; Yamaki H; Komatsuda H; Wakisaka R; Nagato T; Ohkuri T; Kosaka A; Ohara K; Kishibe K; Takahara M; Katada A; Hayashi T; Celis E; Kobayashi H; Harabuchi Y
Cancer Immunol Immunother; 2021 Dec; 70(12):3421-3434. PubMed ID: 33866408
[TBL] [Abstract][Full Text] [Related]
36. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
Zarour HM; Storkus WJ; Brusic V; Williams E; Kirkwood JM
Cancer Res; 2000 Sep; 60(17):4946-52. PubMed ID: 10987311
[TBL] [Abstract][Full Text] [Related]
37. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.
Manici S; Sturniolo T; Imro MA; Hammer J; Sinigaglia F; Noppen C; Spagnoli G; Mazzi B; Bellone M; Dellabona P; Protti MP
J Exp Med; 1999 Mar; 189(5):871-6. PubMed ID: 10049951
[TBL] [Abstract][Full Text] [Related]
38. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen.
Kobayashi H; Omiya R; Ruiz M; Huarte E; Sarobe P; Lasarte JJ; Herraiz M; Sangro B; Prieto J; Borras-Cuesta F; Celis E
Clin Cancer Res; 2002 Oct; 8(10):3219-25. PubMed ID: 12374692
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
[TBL] [Abstract][Full Text] [Related]
40. Cyclin-dependent kinaselike 5 is a novel target of immunotherapy in adult T-cell leukemia.
Kawahara M; Hori T; Matsubara Y; Okawa K; Uchiyama T
J Immunother; 2007; 30(5):499-505. PubMed ID: 17589290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
